Advanced Practice Providers

Adverse Event Management

Brain Cancer

Breast Cancer

Childhood/AYA Cancer

Disparities in cancer care

Drug Safety

Gastrointestinal Cancer

Genetics

Genitourinary Cancer

Gynecologic Cancers

Head and Neck Cancers

Hematology

Immuno-Oncology

Lung Cancer

Nurse Navigation

Prevention

Radiation Oncology

Sarcomas

Skin Cancer/Melanoma

Supportive Care

Survivorship

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies 

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium 

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.

Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.

Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer

News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

Webinars

Subscribe

Partners

Articles

A television commercial produced by Florida Cancer Specialists & Research Institute, LLC (FCS) has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.

Florida Cancer Specialists & Research Institute Television Commercial Recognized with Silver ADDY® Award

The gift is from the estate of Tom and Catherine Culley, longtime residents of the East Coast and worldwide travelers.

Cancer Center gets $1.1M gift for holistic cancer care

Agnes Pilecki, BSN, RN, a nurse on Barbara Ann Karmanos Cancer Institute’s bone marrow transplant unit, has been named the Metro Detroit Oncology Nursing Society’s (MDONS) Outstanding Oncology Nurse of the Year.

Karmanos nurse wins MDONS Outstanding Oncology Nurse of the Year Award

The Barbara Ann Karmanos Cancer Institute is now seeing patients at the new Karmanos Cancer Institute – Roseville.

Karmanos Cancer Institute Opens Roseville Medical Oncology Clinic, Welcomes New Oncologist

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

LinkedIn

Specialty

Clinical

Gynecologic Cancer

1rem

Two small genetic variations predict which patients are most likely to develop second cancers.

Predicting Secondary Cancers in Hodgkin Lymphoma Survivors

Reynaldo Garcia From Lineberger Comprehensive Cancer Center on CML BCR-ABL Testing Recommendation

Reynaldo Garcia on CML BCR-ABL Testing

Reynaldo Garcia from the University of North Carolina Lineberger Comprehensive Cancer Center on BCR-ABL Testing in Chronic Myelogenous Leukemia

Reynaldo Garcia on BCR-ABL Testing in CML

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

Do Breast Implants Increase Cancer Risk?

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

John Theurer Cancer Center Opens New Comprehensive Facility

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies. 

Interview With Siddhartha Mukherjee, Author of The Emperor of All Maladies 

It takes a special skillset for nurses to care for patients whose disease continues to relapse after multiple lines of therapy, shares Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN.

“I tell my younger staff who aren’t used to seeing patients this sick, ‘even if that patient doesn’t survive, what an honor for us to be a part of their journey,’” she tells 

, Jackson, an oncology and bone marrow transplant clinical nurse specialist and unit director at UCLA Medical Center, recalls the story of a patient with acute lymphoblastic leukemia (ALL) who relapsed following treatment with induction chemotherapy and whose disease did not respond to blinatumomab (Blincyto). The team chose to give this patient an off-the-shelf CD22-directed CAR T-cell therapy—which was successful, until the patient ultimately relapsed 6 weeks later.

Jackson emphasizes how, in addition to his physical symptoms, this patient was burdened by worry for his family. As the primary breadwinner in a family with a 2-year-old daughter, he was stressed about how to continue caring for his family. Moreover, he grappled with a language barrier prevented the patient from understanding the complexity of the treatments that the team was prescribing for him. Therefore, Jacksons’ team had to find innovative ways to ensure that the patient, and his family, felt well supported throughout his treatment.

“The biggest challenge we had was [ensuring] his understanding of how sick he really was, the complexity of the treatment, and that he wouldn’t be able to go back to work right away,” she says.

[The patient] presented with bone pain [and] was experiencing chronic fatigue, excruciating acute bone pain in his lower extremities, and low-grade fevers, which caused him to go into his hospital in his area. Fast forward, he had a bone marrow biopsy done [and] they diagnosed him with Philadelphia chromosome–negative ALL. 

Given that it’s a clinical trial [product], we don’t always know [what to expect]. We know with the FDA approved products, the 2 biggest factors we need to monitor patients for is cytokine release syndrome and neurotoxicity. These were the things we were watching for. 

We did a lot of work with our social worker, he was Mixteca Alto, an indigenous population within the Mexican community, and we wanted to make sure we had the appropriate interpreters. 

ASH Data Offer Treatment Direction for Oncology Nursing Professionals

Oncology Nursing Stories: Acupuncture Helps Thyroid Cancer Survivor Taper Opioid Use

Oncology Nursing Stories: Pregnancy After Lymphoma Chemoradiation

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

FDA Approves Blinatumomab for Patients with Acute Lymphoblastic Leukemia and Minimal Residual Disease

The Shifting Dynamics of Social Support After a Cancer Diagnosis

Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy

Expert Weighs in on Future of CAR T-Cell Therapy Treatment Directions

Preparing Patients for CAR T-Cell Therapy With Confidence

The Future of CAR T-Cell Therapy: Will Off-the-Shelf Options Soon Enter the Playing Field?

Navigator Offers Strategies to Support Non-English Speaking Patients

Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. 

. 2019;133(14):1548-1559. doi:10.1182/blood-2018-10-881961

Phase 1/2 study of UCART22 in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (BALLI-01). ClinicalTrials.gov. Updated September 27, 2022. Accessed March 3, 2023. 

https://clinicaltrials.gov/ct2/show/NCT04150497

In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.

Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia 

, Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss data from the 64th American Society of Hematology Annual Meeting and Exposition that have the greatest potential to change oncology nursing practice.

Kalariya, a nurse practitioner with the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, recently spoke with 

highlighted research from the University of Pennsylvania which showed clinical utility of a frailty phenotype tool and contextualized the role of CAR T-cell therapy for patients with multiple myeloma. He also discussed whether data from a subgroup analysis of patients with multiple myeloma who received the anti-BCMA CAR T-cell therapy in the KarMMa-2 trial (NCT03601078) supports moving it forward in the treatment lineup.

Zitella, a nurse practitioner in the Department of Hematology, Blood & Marrow Transplant, and Cellular Therapies Program at the UCSF Helen Diller Family Comprehensive Cancer Center and an associate clinical professor with the School of Nursing University of California, San Francisco, also spoke with 

, highlighting exciting advances with BTK inhibitors and how nurses can promote safe eating habits after data from ASH demonstrated that the neutropenic diet does not benefit patients. on which data from the 2022 ASH meeting might have the greatest impact on nurses working in hematologic oncology.

Interested in learning more from ASH? Check out our coverage of the 

We want to hear from you! Which ASH data do you think will be practice-changing? Email 

“This study that came out at ASH in a transplant population, which is the most immunocompromised population really highlights the [neutropenic diet] and brings it front and center. Hopefully, this will be enough to convince people to abandon the neutropenic diet.” 

“What we see here is that CAR T-cell therapy, followed by maintenance therapy might be a key in frontline settings to have a longer duration of response.” 

“For relapsed or refractory chronic lymphocytic leukemia, zanubrutinib [Brukinsa] had a better overall response rate and progression-free survival than ibrutinib [Imbruvica].” 

Stephanie Jackson Unpacks Recent Advances in Leukemia Treatments

FDA Grants Pirtobrutinib Accelerated Approval for Relapsed/Refractory MCL

Noncovalent BTK Inhibitors May Fill Unmet Needs in CLL and Other Top ASH Takeaways

Optimizing Frailty Tools Are A Vital Component of Improving Care Across Hematologic Malignancies

Phase 3 Data Support Leaving the “Neutrodiet” Behind After Stem Cell Transplant

Induction and Maintenance With Ibrutinib Proves Effective for Mantle Cell Lymphoma

Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL

Aaron Gerds on JAK Inhibitor Therapy for Anemic Patients With Myelofibrosis

Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. 

. 2008;26(35):5684-5688. doi:10.1200/JCO.2008.16.4681

Usmani S, Patel K, Hari P, et al. KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. 

. 2022;140(suppl 1):875-877. doi:10.1182/blood-2022-162469

Dhodapkar M, Alsina M, Berdeja J, et al. KarMMa-2 cohort 2c: efficacy and safety of idecabtagene vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation. 

. 2022;140 (suppl 1):7441–7443. doi:10.1182/blood-2022-162615

Stella F, Marasco V, Levati GV, et al. Non-restrictive diet does not increase infections in patients with neutropenia after stem cell transplantation: final analysis of the Neutrodiet multicenter, randomized trial. Presented at ASH 2022. December 10-13, 2022. Abstract 169.

Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. 

. Published online December 13, 2022. doi:10.1056/NEJMoa2211582

Mato AR, Woyach, JA, Brown, JR, et al. Efficacy of pirtobrutinib in covalent BTK-Inhibitor pre-treated relapsed / refractory CLL/SLL: additional patients and extended follow-up from the phase 1/2 BRUIN study. 

Dreyling M, Doorduijn, JK,Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. 

Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.

ASH Data Offer Treatment Direction for Oncology Nursing Professionals  

, we ring in the New Year 2023 by combing through 2022 FDA approvals. Listen as associate editor, Lindsay Fischer, recounts key approvals on a month-by-month basis, with input from some of the investigators from behind the research. To read the full information surrounding the approvals, be sure to check out our news coverage below. Other resources can also be found below.

, and for all the engagement in 2022. We look forward to bringing you more oncology news in 2023.

We want to hear from you! Which drugs approved in 2022 have been practice changing? Have you had any difficulty or success in incorporating these novel agents into clinical use? Any challenges with supporting patients on these regimens? Email 

FDA Approves Tebentafusp to Treat HLA-A*02:01 Positive Uveal Melanoma

Cilta-Cel Snags FDA Approval for Relapsed/Refractory Multiple Myeloma

Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy Is Now Approved for Resectable NSCLC

FDA Greenlights Olaparib for BRCA-Mutated, HER2-Negative Breast Cancer

FDA OKs Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma

FDA Approves Pembrolizumab in MSI H/dMMR Advanced Endometrial Carcinoma

FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Axi-Cel Snags FDA Approval for Second-Line LBCL

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Breast Cancer

FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations

FDA Grants Azacitidine Approval For Pediatric Patients With Myelomonocytic Leukemia

FDA Grants 2 Frontline Nivolumab-Based Regimens Approval for Unresectable Advanced or Metastatic ESCC

Tisagenlecleucel Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma

FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors

FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma

Crizotinib Approved For ALK+ Inflammatory Myofibroblastic Tumors

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

Trastuzumab Deruxtecan Is Approved for Patients With Metastatic HER2-Low Breast Cancer

FDA Approves Darolutamide Tablets for Select Patients With Prostate Cancer

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease

FDA Gives Pemigatinib Greenlight for FGFR1 Rearranged Myeloid/Lymphoid Neoplasms

Durvalumab Plus Gemcitabine/Cisplatin Approved by the FDA for Advanced or Metastatic Biliary Tract Cancers

Sodium Thiosulfate Gets Green Light for Chemotherapy-Induced Hearing Loss in Pediatric Patients

Selpercatinib Is Approved for 2 RET Fusion–Positive Solid Tumors, Non–Small Cell Lung Cancer

FDA Approves Futibatinib for Pretreated, Advanced or Metastatic Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangements

FDA Approves Durvalumab in Combination with Tremelimumab for Unresectable HCC

Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma

Cemiplimab Gets Go Ahead In Combination With Chemotherapy For Advanced NSCLC

Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric Patients

Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication

Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian Cancer

Olutasidenib Approved for IDH1-Mutated Acute Myeloid Leukemia

Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLC

Watch: Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in Melanoma

Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer

Nurse Takeaways: Latest Pembrolizumab Indication in Endometrial Cancer

Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer

Goodwin Provides Nursing Perspective on Recent FDA Approvals in NSCLC

Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma

Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.  

A Look Back at 2022 FDA Approvals in Oncology

, Ellen Miller, MSN, FNP-BC, a nurse practitioner with Vanderbilt University’s Radiation Oncology Survivorship Clinic, shares her experience with a 26-year-old woman who wanted to get pregnant after undergoing chemoradiation for stage II extranodal natural killer T-cell lymphoma of the nasal cavity as a teenager. Miller underscores why some patients may not choose or be able to pursue fertility preservation when they receive a cancer diagnosis, and what follow-up conversations might be necessary for survivors who have family building goals following cancer treatment. 

References and resources are provided below. 

“When I talked with her, I asked her, specifically, ‘Were you offered fertility preservation?’ And she said, ‘Absolutely.’ [But] she declined, she said, ‘I was 19, I didn’t think I wanted kids.’ But she had [since] met her husband, a wonderful man, and decided that she wanted to have kids.” 

“The out-of-pocket [cost] for fertility preservation is $10,000 to $15,000, on average. That’s hard for [anyone], not to mention a young [woman].” 

“Not only can chemotherapy damage existing eggs, but it can also lead patients to have early or premature menopause.” 

“If patients were to have left-sided chest radiation, [for] a lymphoma or maybe even a breast cancer, we would do some cardiac monitoring, since both the chemotherapy and the radiation can be damaging to the heart, and pregnancy can cause the heart to work harder.” 

“[The] trajectory for her experience was pretty standard, and we were thankful for that. But there are some reasons why some women would need further monitoring.” 

Improving Onco-Fertility Conversations With Adolescents and Young Adult Patients With Cancer

Fertility and Family Planning: Supportive Patient Conversations

Quality Oncology Care: Discussing Fertility Preservation for Patients With Breast Cancer

Fertility Preservation Guidelines Urge for Early Discussions With Young Patients with Cancer

Jennifer Levine on Fertility Challenges in Survivors of Childhood Cancer

In this episode of "The Vitals," Ellen Miller, MSN, FNP-BC, talks about meeting a patient who realized she wanted to get pregnant after undergoing chemoradiation as a teenager.

Hematology

More News

Latest Conference Coverage